Noven: FDA Nixes Delay on Generic Pain Patch

Regulators have denied petitions to prevent or delay approval of certain generic versions of Johnson & Johnson's Duragesic, a chronic pain patch. Noven Pharmaceuticals, which disclosed the decision by the FDA, said the denied petitions were from Alza; Brookoff and Voth; London & Mead; and Steven Shafer. Miami-based Noven has applied to the FDA to market its own generic for Duragesic, a fentanyl patch.

South Florida Business Journal (http://www.bizjournals.com/southflorida/stories/2005/01/31/daily1.html)